KẾT QUẢ ĐIỀU TRỊ HÓA CHẤT BỔ TRỢ TRƯỚC PHÁC ĐỒ 4AC – 4TH BỆNH NHÂN UNG THƯ VÚ GIAI ĐOẠN III TẠI BỆNH VIỆN UNG BƯỚU HÀ NỘI

Abstract

Objectives: Our study aims to describe the clinical and paraclinical characteristics of stage III breast cancer patients and evaluate the treatment outcomes and toxicity of neoadjuvant 4AC- 4TH regimen in this group. Patients and Methods: Retrospective, descriptive sudy on 51 patients with stage III breast cancer, were treated with neoadjuvant 4AC – 4TH regimen at Ha Noi Onconlogy Hospital. Results: The mean age was 51,7. The proportion of stage IIIA, IIIB, IIIC is 39,2%, 35,3% and 25,5%, respectively . 92,2% patients histoloy was invasive carrcinoma of no special type (NST) and 70,6% was in grade II. After treatment, the complete clinical response was 15,7% after 8 cycles of 4AC- 4TH. All of our patients was moved to modified radical mastectomy after neoadjuvant chemotheraphy. The pathological complete response (pCR) was 43,1%. Most adverse events were manageable and tolerable. The most common toxicity was amenia, leukopenia, neutropenia, mainly at grade 1-2. The proportion of neutropenia at levels 3 and 4 over the total number of chemical cycles is 4.9% and 0.2%, respectively. Non hematological toxicities such as vomiting, fatigue, stomatitis and alopecia were also common and all of them were mild and moderate. Conclusion: 4AC- 4TH regimen in neoadjuvant setting gives a high pCR rate with tolerable toxicity, therefore this regimen can be widely used as neoadjuvant chemotheraphy prior to surgery with Her-2 positive breast cancer in our country, specilly with inoperable stage at initial diagnosis.